Clinical trials: Acute Coronary Syndromes
Acute Myocardial Injuries
Acute Coronary Syndrome CardioFlux TM Study (ACCMED)
Approximately 16.5 million people suffer from coronary artery disease (CAD) and about 10 million present each year to emergency departments with symptoms like chest pain and shortness of breath, commonly suggestive of acute…
- Trial name
- MAGNETO (NCT04739267)
- Testing
- CardioFlux
- Where
- United States
- Volunteers
- 390 people
- Sponsor
- Genetesis Inc.
Acute Coronary Syndrome
The Use of the Master Caution System (MCS) for Continuous Monitoring and Detection of Dysrhythmias and Ischemic Events
The purpose of this study is to evaluate the effectiveness and usability of the Master Caution System for 12 leads continuous monitoring of ECG signal in the ICCU.
- Trial name
- NCT03001206
- Testing
- Master Caution System
- Where
- Israel
- Volunteers
- 84 people
- Sponsor
- HealthWatch Ltd.
Acute Coronary Syndrome
A Clinical Study of MT1002 in Subjects With Acute Coronary Syndrome Undergoing PCI
An Open-label, Sequential Dose Escalation/De-escalation Clinical Trial of MT1002 in Subjects With Acute Coronary Syndrome Undergoing PCI.
- Trial name
- NCT06533358
- Testing
- MT1002 Injection
- Where
- 2 sites in China
- Volunteers
- 20 people
- Sponsor
- Shaanxi Micot Pharmaceutical Technology Co., Ltd.
Acute Coronary Syndrome
A Double-Blind Study of E5555 in Japanese Patients With Acute Coronary Syndrome
The purpose of this study is to assess the safety and tolerability of E5555 in Japanese patients with acute coronary syndrome.
- Trial name
- NCT00619164
- Testing
- E5555
- Where
- 33 sites in Japan
- Volunteers
- 240 people
- Sponsor
- Eisai Co., Ltd.
Acute Coronary Syndrome
VitalScan MCG Rule-out Multi-centre Pivotal Study - UK
The study is a prospective multi-centre observational study to evaluate a portable magnetocardiograph device for the rule-out of acute coronary syndrome (ACS) in patients who present to the emergency department with chest pain…
- Trial name
- MAGNET-ACS (NCT02921438)
- Testing
- VitalScan Magnetocardiograph
- Where
- 5 sites in United Kingdom
- Volunteers
- 756 people
- Sponsor
- Creavo Medical Technologies Ltd
Heart Failure, Acute Heart Failure
PURE-HF: Peripheral Ultrafiltration for the RElief From Congestion in Heart Failure
This study evaluates whether tailored, peripheral ultrafiltration complementary to low-dose diuretics is associated with a reduction in cardiovascular mortality in 90 days after randomization and heart failure events in 90 days…
- Trial name
- NCT03161158
- Testing
- CHIARA-System, Usual care IV diuretics
- Where
- 11 sites in Germany, Sweden
- Volunteers
- 62 people
- Sponsor
- Fresenius Medical Care Deutschland GmbH
Coronary Disease
Study of Otamixaban Versus Unfractionated Heparin (UFH) and Eptifibatide in Non-ST Elevation Acute Coronary Syndrome
Primary objective: To demonstrate the clinical efficacy of otamixaban (dose effect via 5 intravenous [IV] regimens) in patients with moderate-to-high-risk non-ST elevation acute coronary syndromes (ACS) and planned early invasive…
- Trial name
- SEPIA-ACS1 (NCT00317395)
- Testing
- Otamixaban (XRP0673), unfractionated heparin, eptifibatide
- Where
- 36 sites in United States, Argentina and 34 more
- Volunteers
- 3,241 people
- Sponsor
- Sanofi
Cardiac Arrest, Renal Failure
The Vital Signs to Identify, Target, and Assess Level (VITAL) Care Study III
To evaluate the effect of automated recording on frequency of recorded scores, number of automated notifications and serious events.
- Conditions
- Cardiac Arrest, Renal Failure, Respiration Failure, Myocardial Infarction
- Trial name
- NCT02973243
- Testing
- Automatic RR Measurement
- Where
- United Kingdom
- Volunteers
- 446 people
- Sponsor
- Philips Healthcare
Acute Coronary Syndrome
The Effect on Blood Cells, Known as Platelets, Using Prasugrel vs Clopidogrel in Patients With the Heart Problem Acute Coronary Syndrome (ACS)
This is a multicenter, randomized, double-blind, cross-over study to compare the pharmacodynamic response in subjects with Acute Coronary Syndrome receiving a 10-mg maintenance dose (MD) of prasugrel compared with a 150-mg…
- Trial name
- NCT00385944
- Testing
- Prasugrel, Clopidogrel
- Where
- 2 sites in France
- Volunteers
- 56 people
- Sponsor
- Eli Lilly and Company
Acute Coronary Syndromes
Effect of rHDL on Atherosclerosis - Safety and Efficacy: THE ERASE TRIAL
Currently available therapies to treat Acute Coronary Syndromes(ACS) have several limitations including; the relatively long treatment duration required before apparent significant benefit; the inability to achieve reversal of…
- Trial name
- NCT00225719
- Testing
- rHDL
- Where
- Canada
- Volunteers
- 180 people
- Sponsor
- CSL Limited
Acute Coronary Syndrome
Study Evaluating Safety, Tolerability and Efficacy of YM150 in Subjects With Acute Coronary Syndromes
The purpose of this study is to evaluate the safety and efficacy of various doses of YM150 (the experimental drug) in the prevention of ischemic vascular events in subjects with recent acute coronary syndromes.
- Trial name
- RUBY-1 (NCT00994292)
- Testing
- YM150
- Where
- 131 sites in Argentina, Australia and 19 more
- Volunteers
- 1,276 people
- Sponsor
- Astellas Pharma Europe B.V.
Acute Coronary Syndrome, Old Myocardial Infarction
Brilinta Clinical Experience Investigation
To confirm the following safety topics in patients to be treated with BRILINTA tablets 60 mg or 90 mg (hereinafter referred to as "BRILINTA") in clinical practice in the post-marketing phase. 1.
- Trial name
- BRLCEIACS/OMI (NCT03212287)
- Where
- 71 sites in Japan
- Volunteers
- 663 people
- Sponsor
- AstraZeneca
Coronary Artery Disease, Chronic Stable Angina
LEADERS FREE IV (RCT): BioFreedom™ Ultra vs BioFreedom™ in HBR Patients
This study aims to demonstrate that the BioFreedom™ Ultra Drug Coated Stent (DCS) is non-inferior to the BioFreedom™ DCS, with respect to in-stent late lumen loss, and that it has safety characteristics similar to the BioFreedom™…
- Conditions
- Coronary Artery Disease, Chronic Stable Angina, Unstable Angina, Silent Ischemia
- Trial name
- NCT06657326
- Testing
- BioFreedom™ Ultra cobalt-chromium Biolimus A9™-coated stent, BioFreedom™ stainless steel Biolimus A9™-coated stent
- Where
- 6 sites in Malaysia
- Volunteers
- 444 people
- Sponsor
- Biosensors Europe SA
Acute Coronary Syndrome (ACS)
Evaluation on the Safety of Ticagrelor Among Chinese ACS Patients
The primary objective is to describe the safety and tolerability of ticagrelor, by assessment of adverse events (characteristics, reporting rate, severity, relationship and risk factors), especially the bleeding events as defined…
- Trial name
- YingLong (NCT02430493)
- Where
- 15 sites in China
- Volunteers
- 1,066 people
- Sponsor
- AstraZeneca
Coronary Artery Disease
PIONEER III Trial to Assess Safety and Efficacy of the BuMA Supreme™ Drug Coated Coronary Stent in Patients With Coronary Disease
The primary objective of this trial is to compare the safety and efficacy of the SINOMED BuMA Supreme biodegradable coronary stent in patients with up to 3 coronary lesions to either the XIENCE or Promus durable polymer coronary…
- Trial name
- NCT03168776
- Testing
- BuMA Supreme DES, Xience or Promus DES
- Where
- 58 sites in United States, Belgium and 6 more
- Volunteers
- 1,629 people
- Sponsor
- Sino Medical Sciences Technology Inc.
Acute Coronary Syndromes
Long-term Follow-up of antithrombotIc Management Patterns in Acute Coronary Syndrome Patients in Asia-China Extension
This study is to describe the long-term antithrombotic management patterns in a real-life setting for patients hospitalized with an acute coronary syndrome in China.
- Trial name
- EPICOR (NCT02305680)
- Where
- 33 sites in China
- Volunteers
- 2,334 people
- Sponsor
- AstraZeneca
Stent Thrombosis, Ischemic Stroke
Association Between Genetic Variant Scores and P2Y12 Inhibitor Effects
The goal of this study is to predict and prevent adverse drug events by investigating the impact of genetic variants, demographics, and environmental factors in subjects status post myocardial infarction and percutaneous coronary…
- Conditions
- Stent Thrombosis, Ischemic Stroke, Myocardial Infarction, Acute Coronary Syndrome
- Trial name
- CARES1 (NCT04580602)
- Where
- South Korea
- Volunteers
- 200 people
- Sponsor
- Cipherome, Inc.
Acute Coronary Syndrome
Comparative Assessment of Inclisiran on Top of Standard of Care Versus Standard of Care Alone for LDL-C Evaluation in Acute Coronary Syndrome Patients in Saudi Arabia
This study aims to evaluate the effectiveness and safety of implementing a systematic augmented low-density lipoprotein cholesterol (LDL-C) management care pathway initiated in hospitals for patients with Acute Coronary Syndrome.
- Trial name
- NCT07684469
- Testing
- inclisiran, SOC
- Volunteers
- 300 people
- Sponsor
- Novartis Pharmaceuticals
Chronic Heart Failure With Reduced Ejection Fraction
Safety and Tolerability During Open-label Treatment With LCZ696 in Patients With CHF and Reduced Ejection Fraction
The purpose of this study was to collect safety and tolerability data on LCZ696 in eligible PARADIGM-HF patients who received open-label investigational drug.
- Trial name
- NCT02226120
- Testing
- LCZ696
- Where
- 394 sites in United States, Argentina and 39 more
- Volunteers
- 1,980 people
- Sponsor
- Novartis Pharmaceuticals
Acute Coronary Syndrome (ACS)
Maintenance of Platelet Inhibition With Cangrelor
The purpose of this study is to demonstrate that patients receiving cangrelor infusion before coronary artery bypass grafting have an acceptable safety profile and can undergo surgery without excessive bleeding peri-operatively.
- Trial name
- Bridge (NCT00767507)
- Testing
- cangrelor
- Where
- United States
- Volunteers
- 221 people
- Sponsor
- The Medicines Company